Index

Show indicators by:

  • Cancer Control Domain
  • Disease Site
  • Dashboard
  • Disease Site
    • Breast
      • Breast cancer screening
      • Screening in underserved populations
      • Breast cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Breast cancer resections that are mastectomies
        • The use of breast-conserving surgery versus mastectomies for breast cancer resections
      • Radiation therapy
        • Post-operative radiation therapy for stage I or II breast cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Breast cancer screening outside recommended guidelines
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Colorectal
      • Colorectal cancer screening
      • Geographic variation in colorectal cancer risk
      • Screening in underserved populations
      • Colorectal cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Removal and examination of 12 or more lymph nodes in colon resections
        • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
      • Radiation therapy
        • Pre-operative radiation therapy for patients with stage II or III rectal cancer
      • Post-operative chemotherapy for stage III colon cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Lung
      • Capture of stage
      • Stage distribution
      • Geographic variation in lung cancer risk
      • Resection rates for stage II or IIIA Non-snmall cell lung cancer patients
      • Post-operative chemotherapy for stage II or IIIA non-small cell lung cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Prostate
      • PSA testing
      • Prostate risk profile
      • Capture of stage
      • Stage distribution
      • Prostate wait times for surgery
      • Prostate wait times for radiation therapy
      • Radical prostatectomy: open versus laparoscopic surgery
      • Prostate patterns of care: radiation and surgical treatment
      • Prostate access to palliative radiation
      • Prostate clinical trials participation
      • Adult clinical trial participation
      • Prostate cancer research investment
      • Cancer research investment
      • Incidence & Mortality Rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Cervical
      • Human papillomavirus (HPV) vaccination
      • Cervical cancer screening
      • Screening in underserved populations
    • Pancreas
      • Incidence and mortality rates
    • Stage Distribution
  • Province & Territory
  • 1. Prevention
  • 2. Screening
  • 3. Diagnosis
  • 4. Treatment
  • 5. Person-Centred Perspective
  • 6. Research
  • 7. Appropriateness
  • 8. Long-term outcomes
  • Smoking prevalence
  • Smoking behaviours in current cancer patients
  • Smoking cessation
  • Second-hand smoke exposure
  • Geographic variation in lung cancer risk
  • Alcohol consumption
  • Adult overweight and obesity
  • Active transportation
  • Physical inactivity
  • Human papillomavirus (HPV) vaccination
  • Fruit and vegetable consumption
  • Geographic variation in colorectal cancer risk
  • Cervical cancer screening
  • Breast cancer screening
  • Colorectal cancer screening
  • PSA testing
  • Screening in underserved populations
  • Breast cancer diagnosis wait times
  • Colorectal cancer diagnosis wait times
  • Capture of stage
  • Stage distribution
  • Prostate risk profile
  • Surgery
  • Radiation therapy
  • Systemic therapy
  • Removal and examination of 12 or more lymph nodes in colon resections
  • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
  • The use of breast-conserving surgery versus mastectomies for breast cancer resections
  • Breast cancer resections that are mastectomies
  • High-risk, resource-intensive surgeries for esophageal, pancreatic, liver, lung and ovarian cancers in Canada
  • Prostate wait times for surgery
  • Radical prostatectomy: open versus laparoscopic surgery
  • Radiation therapy wait times
  • Radiation therapy utilization and capacity
  • Pre-operative radiation therapy for patients with stage II or III rectal cancer
  • Post-operative radiation therapy for patients with stage I or II breast cancer
  • Prostate wait times for radiation therapy
  • Prostate patterns of care: radiation and surgical treatment
  • Post-operative chemotherapy for stage III colon cancer patients
  • Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer
  • Screening for distress
  • Patient satisfaction
  • Place of death
  • Prostate access to palliative radiation
  • Adult clinical trial participation
  • Prostate clinical trials participation
  • Pediatric clinical trial participation
  • Cancer research investment
  • Prostate cancer research investment
  • Breast cancer screening outside of guidelines
  • Breast cancer mastectomies done as day surgery
  • Intensive care use in the last two weeks of life
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Pancreatic cancer
  • Five-year net survival by income quintile for several cancers in Canada
System Performance Logo
System Performance
  • About
  • Reports
  • Français
  • Home
  • Cancer control domain
  • 4. Treatment
  • Systemic therapy
  • Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer

Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer

  • Charts and Tables

    Charts and Tables

    Figure 4.27

    Percentage of Stage II or IIIA non-small cell lung cancer patients who received chemotherapy following surgical resection, by jurisdiction — 2011 to 2014 diagnosis years

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    * Suppressed owing to small numbers.

    “—” Data not available.

    E  Interpret with caution due to small counts

    Data source: Provincial cancer agencies and programs

    Data Table

    JurisdictionYearNumber of patients receiving chemotherapyPercent (%)Quality indicatorLower bound of 95% confidence intervalUpper bound of 95% confidence interval
    BC20117644.737.152.5
    BC20126631.625.338.3
    BC20136136.729.444.6
    BC2014----
    AB20115047.237.457.1
    AB20126142.434.250.9
    AB20136142.133.950.5
    AB20145936.629.244.6
    SK20111343.325.562.6
    SK20121945.229.861.3
    SK20131636.422.452.2
    SK20141741.526.357.9
    MB20113141.330.153.3
    MB20122836.826.148.7
    MB20133246.434.358.8
    MB20143844.733.955.9
    ON201130950.146.154.1
    ON201233851.747.855.6
    ON201334250.146.354.0
    ON201435851.347.555.1
    QC2011----
    QC2012----
    QC2013----
    QC2014----
    NB2011----
    NB2012----
    NB2013----
    NB2014----
    NS20112440.027.653.5
    NS20122037.024.351.3
    NS20131327.715.642.6
    NS20142339.026.552.6
    PE2011545.516.776.6
    PE2012****
    PE2013****
    PE2014****
    NL201100.0E0.019.0
    NL201200.0E0.021.0
    NL201300.0E0.034.0
    NL2014718.98.035.2
    YT2011----
    YT2012----
    YT2013----
    YT2014----
    NT2011----
    NT2012----
    NT2013----
    NT2014----
    NU2011----
    NU2012----
    NU2013----
    NU2014----

    + Expand Table

    * Suppressed owing to small numbers.

    “—” Data not available.

    E  Interpret with caution due to small counts

    Data source: Provincial cancer agencies and programs

    Figure 4.28

    Percentage of patients with Stage II or IIIA non-small cell lung cancer who received chemotherapy following surgical resection, by age group, jurisdictions combined† — 2011 to 2014  diagnosis years

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    † Includes AB, SK, MB, ON, NS and PE.
    Data source: Provincial cancer agencies and programs.

    Data Table

    Age groupYearPercent (%)Lower bound of 95% confidence intervalUpper bound of 95% confidence interval
    18-59201162.655.769.1
    18-59201262.455.169.4
    18-59201357.249.964.3
    18-59201454.047.060.8
    60-69201155.449.860.8
    60-69201257.451.862.7
    60-69201355.750.460.9
    60-69201457.052.161.8
    70-79201138.432.844.2
    70-79201239.834.844.9
    70-79201340.335.245.5
    70-79201440.635.446.1
    80+201110.34.220.1
    80+201212.86.322.3
    80+201313.46.922.7
    80+20147.62.815.8

    + Expand Table

    † Includes AB, SK, MB, ON, NS and PE.
    Data source: Provincial cancer agencies and programs.

  • Data specifications

    Data specifications

    Definition: The percentage of patients diagnosed with stage II or IIIA non-small cell lung cancer (NSCLC) who received post-operative chemotherapy within 120 days of resections

    Rationale for measurement: The delivery of chemotherapy following resection has been shown to improve outcomes (i.e., disease-free and overall survival) and prevent recurrences in patients with Stage II and IIIA NSCLC, compared with surgery alone. Clinical practice guidelines therefore recommend post-operative chemotherapy for patients with Stage II and IIIA NSCLC.

    Measurement timeframe: Diagnosis years 2011 to 2014

    Denominator: Stage II and IIIA non-small cell lung cancer cases diagnosed during the timeframe and having a lung resection within one year of diagnosis.

    Numerator: Stage II and IIIA non-small cell lung cancer cases having post-operative chemotherapy within 120 days of resections, which were diagnosed during the timeframe and receiving resections within one year of diagnosis

    Exclusion criteria: Cases with age ≤ 17 were excluded.

    Data availability:

    • 2011-2014: AB, SK, MB, ON, NS, NL and PE
    • 2011-2013: BC

    Stratification: 

    Data were aggregated at national level:

    1. By year and age group: 18-59, 60-69, 70-79, 80+

    Data were aggregated at provincial level:

    1. By year

    Data source: Provincial cancer agencies and programs

    Data retrieval date: October 2017

    Variables details:

    Cancer definition:

    1. Non-small cell lung cancer (NSCLC) was defined as C34 in ICD-O3 with behavior code 3 (invasive). Cancer cases with lymphoma codes M-95 to M-98, sarcoma codes (see Appendix A), and 8002, 8041, 8043, 8044, 8045, and 8803, 8042 were excluded
    2. Non-small lung cancer cases were restricted to stage II and stage IIIA in AJCC.

    Resection identification:

    1. Lung resections were identified in CCI codes as 1GR87, 1GR89, 1GR91, 1GT59, 1GT87, 1GT89, 1GT91, or 1GV87.

    Treatment criteria:

    1. Chemotherapy included oral (as available in data) and IV chemotherapy.
    2. All lung resections were within 1 year of diagnosis. If there were multiple resections, the last resection was counted:
      Last resection date (if multiple) – diagnosis date ≤ 365 days
    3. All post-operative chemotherapy were within 120 days after resections:
      Chemo start date – Last resection date (if multiple) ≤120 day

    Notes from jurisdictions:

    • AB: The ACR codes out of province treatment to provincial residents if they are notified and/or it is mentioned in the documents. The following small-cell morphologies were excluded: 8002, 8041, 8042, 8043, 8044, 8045, 8803. For Step3 cases with both neo-adjuvant and adjuvant chemotherapy were excluded.
    • SK: Chemo includes oral and intravenous (IV). We are unable to differentiate between the two modalities in Saskatchewan.
    • MB: Oral chemotherapy data is only recorded if it is documented in the chart.
    • ON: For oral data-Oral chemotherapy included if available but may not be complete. DAD/NACRS and ALR were included. ODB wasn't included.
    • NS: These numbers differ from what had been provided in the past for a number of reasons. First, we are no longer using site-specific factors in the Collaborative Stage data to identify resections. Instead, we have used DAD/NACRS data. Second, the DAD/NACRS data include a small number of persons who received their surgical resection(s) outside Nova Scotia as well, which is a first. However, we will not have treatment data for these persons if they received treatment outside Nova Scotia, so it's possible the percentage receiving chemo could be slightly underestimated. Third some histology codes associated with NSCLC were excluded along with other squamous cell carcinoma in the past.
    • PE: Oral data would be included if known about.

    Methodology notes: 

    1. Data presented include stage II and IIIA combined
    2. The cancer incidence sites/types were classified by World Health Organization, International Classification of Diseases for Oncology, Third Edition (ICD- O-3).
    3. American Joint Committee on Cancer (AJCC) Cancer Staging Manual 7th edition was used to classify cancer stage groups.
    4. The Canadian Classification of Health Interventions (CCI) codes were used to identify surgery types, except AB.

    Changes to definition compared to previous years: Not applicable

  • Related indicators

    Related Indicators

    Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non–small cell lung cancer patients

    Percentage of Stage II or IIIA non-small cell lung cancer patients who had a surgical resection†, by province — from 2009 to 2012 diagnosis years
    View this indicator
    Lung cancer

    Incidence rates for lung cancer, by stage at diagnosis and province, age-standardized to the 2011 Canadian population — 2015 diagnosis year
    View this indicator
  • About Us
  • Careers
  • Contact
  • Media centre
  • Share your feedback
  • About our new site

  • Français Language toggle.

Other related sites:

  • Canadian Partnership for Tomorrow’s Health
  • Canadian Cancer Research Alliance
  • Canadian Cancer Trials
  • facebook
  • twitter
  • youtube
  • linkedin
    CPAC Logo

    Questions about cancer?

    For information about cancer treatment and support for patients, please contact the Canadian Cancer Society at 1-888-939-3333 or by completing this online form.

  • AODA compliance
  • Privacy policy
  • Terms of use
  • FAQ
  • Site map
  • About this site
© Canadian Partnership Against Cancer Corporation